Insider · CIK 0001998491
Timothy Schmid
chairofficer
Files at JNJ (JOHNSON & JOHNSON). First filing Feb 18, 2025, latest Sep 4, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $9.3M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
JNJ: JOHNSON & JOHNSON
JNJOct 9, 2026 · close 261.44
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | JNJsell JOHNSON & JOHNSON | $9.2M 33,597 shares | -92% | - | |
| 28Weak | JOHNSON & JOHNSON | $63k 403 shares | -3% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +11,070 | $131.94 | $1.5M | 36,517 | 38 d ago |
| Sep 2, 2026 | JNJ JOHNSON & JOHNSON | SOpen-market sale Common Stock | -11,070 | $274.74 | $3.0M | 25,447 | 38 d ago |
| Sep 2, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +22,527 | $151.41 | $3.4M | 47,974 | 38 d ago |
| Sep 2, 2026 | JNJ JOHNSON & JOHNSON | SOpen-market sale Common Stock | -22,527 | $274.74 | $6.2M | 25,447 | 38 d ago |
| Sep 2, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Employee Stock Options (Right to Buy)derivative | -11,070 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | JNJ JOHNSON & JOHNSON | MOption exercise Employee Stock Options (Right to Buy)derivative | -22,527 | $0.00 | $0 | 0 | 38 d ago |
| Feb 15, 2025 | JNJ JOHNSON & JOHNSON | AGrant or award Employee Stock Options (Right to Buy)derivative | +49,878 | $0.00 | $0 | 49,878 | Feb 19, 2025 |
| Feb 15, 2025 | JNJ JOHNSON & JOHNSON | AGrant or award Restricted Share Unitsderivative | +3,077 | $0.00 | $0 | 3,077 | Feb 19, 2025 |
| Feb 14, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +2,806 | $0.00 | $0 | 17,904 | Feb 18, 2025 |
| Feb 13, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +499 | $0.00 | $0 | 13,539 | Feb 18, 2025 |
| Feb 14, 2025 | JNJ JOHNSON & JOHNSON | FTax withholding Common Stock | -193 | $155.26 | $30k | 13,346 | Feb 18, 2025 |
| Feb 14, 2025 | JNJ JOHNSON & JOHNSON | FTax withholding Common Stock | -1,015 | $156.71 | $159k | 16,889 | Feb 18, 2025 |
| Feb 14, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +1,765 | $0.00 | $0 | 15,111 | Feb 18, 2025 |
| Feb 14, 2025 | JNJ JOHNSON & JOHNSON | FTax withholding Common Stock | -639 | $156.71 | $100k | 14,472 | Feb 18, 2025 |
| Feb 15, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Common Stock | +1,029 | $0.00 | $0 | 15,501 | Feb 18, 2025 |
| Feb 14, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Performance Share Unitsderivative | -2,806 | $0.00 | $0 | 0 | Feb 18, 2025 |
| Feb 18, 2025 | JNJ JOHNSON & JOHNSON | SOpen-market sale Common Stock | -403 | $156.15 | $63k | 15,098 | Feb 18, 2025 |
| Feb 13, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Restricted Share Unitsderivative | -499 | $0.00 | $0 | 499 | Feb 18, 2025 |
| Feb 14, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Restricted Share Unitsderivative | -1,765 | $0.00 | $0 | 0 | Feb 18, 2025 |
| Feb 15, 2025 | JNJ JOHNSON & JOHNSON | MOption exercise Restricted Share Unitsderivative | -1,029 | $0.00 | $0 | 2,056 | Feb 18, 2025 |
| Feb 10, 2025 | JNJ JOHNSON & JOHNSON | AGrant or award Performance Share Unitsderivative | +2,806 | $0.00 | $0 | 2,806 | Feb 12, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.